A Phase 3 interventional study of Avelumab (MSB0010718C) and Axitinib (AG-013736) in Renal Cell Cancer, sponsored by Pfizer. Completed at 270 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing avelumab in Carcinoma, Renal Cell — 1 open to participants now, 2 under way, 1 of them phase 3. avelumab · Carcinoma, Renal Cell.
Among the 10 studies testing avelumab in Carcinoma, Renal Cell, this one is the 2nd largest by enrollment, is the only one that started in 2016, is one of 2 in phase 3, and was the 3rd registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →1 of the 10 studies testing avelumab in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:
Institut Bergonié · Sites in France
Ages 18+
By country, each count listing its studies:
avelumab: first FDA approval 2017 (BAVENCIO), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 2
First in 2013; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 886 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 48 across the 10 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
80 studies in Carcinoma, Renal Cell by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 74 finished, 54 (73%) have results posted.
Among the 80 studies in Carcinoma, Renal Cell by Pfizer, this one has the largest enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 51st registered.
Pfizer’s Carcinoma, Renal Cell studies by the year they started, since 2002.
1 of the studies testing avelumab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing avelumab in Carcinoma, Renal Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 80 in Carcinoma, Renal Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
Drug: Avelumab (MSB0010718C) · Drug: Axitinib (AG-013736)
Sunitinib given at 50 mg PO QD on schedule 4/2
Drug: Sunitinib
IV treatment Avelumab administered at 10 mg/kg IV every two weeks
Oral treatment Axitinib given 5 mg PO BID
Also known as: Inlyta
Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
Also known as: Sutent
Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants
PFS: time from the date of randomization to the date of the first documentation of progressive disease (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1) or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20 percent (%), increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute more than (\>) of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression.
Time frame: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)
Overall Survival (OS) in PD-L1 Positive Participants
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
Time frame: From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)
PFS as Assessed by BICR in Participants Irrespective of PD-L1 Expression
PFS: time from the date of randomization to the date of the first documentation of PD or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)
OS in Participants Irrespective of PD-L1 Expression
OS was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
Time frame: From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)
Percentage of Participants With Objective Response (OR) as Assessed by BICR Irrespective of PD-L1 Expression
OR was defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.
Time frame: From date of randomization until PD (maximum up to approximately 26 months)
Percentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression
OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by investigator recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.
Time frame: From date of randomization until PD (maximum up to approximately 89 months)
Percentage of Participants With Disease Control (DC) as Assessed by BICR Irrespective of PD-L1 Expression
DC was defined as a best overall response of CR, PR, non-CR/non-PD or stable disease (SD) according to RECIST v1.1 as assessed by BICR. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.
Time frame: From date of randomization until PD (maximum up to approximately 26 months)
Percentage of Participants With DC as Assessed by Investigator Irrespective of PD-L1 Expression
DC was defined as a best overall response of CR, PR, non-CR/non-PD or SD according to RECIST v1.1 as assessed by investigator. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.
Time frame: From date of randomization until PD (maximum up to approximately 89 months)
Time to Tumor Response (TTR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression
TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by BICR (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
Time frame: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)
TTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression
TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by investigator (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
Time frame: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 89 months)
Duration of Response (DR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression
BICR assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression assessed by BICR or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)
DR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression
Investigator assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression (PD) assessed by investigator or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 89 months)
PFS as Assessed by Investigator in Participants Irrespective of PD-L1 Expression
Investigator assessed PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: From date of randomization until PD, whichever occurred first (maximum up to approximately 89 months)
Progression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression
PFS2 is defined as the time (in months) from randomization to discontinuation of next-line treatment after first objective disease progression by investigator assessment, second objective disease progression by investigator assessment after initiation of next-line treatment, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: From date of randomization until PD or death, whichever occurred first (maximum up to approximately 89 months)
Number of Participants With Treatment-Emergent Adverse Events (AEs) Graded Based on National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (V) 4.03
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event was during the on-treatment period (time from the first dose of study treatment through 90 days after last dose of study treatment or start day of new anti-cancer drug therapy-1 day). As per NCI-CTCAE v4.03, grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death.
Time frame: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)
Number of Participants According to Grade Shift in Hematology Parameters
Following hematology parameters were assessed: hemoglobin decreased (anemia), hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell (WBC) decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 4.03 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Baseline was defined as last assessment prior to first dose of study treatment. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.
Time frame: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)
Number of Participants According to Grade Shift in Chemistry Parameters
Following chemistry parameters were assessed: alanine aminotransferase(ALT) increased, alkaline phosphatase(ALP) increased, aspartate aminotransferase(AST) increased, blood bilirubin increased, cholesterol high, creatinine phosphokinase(CPK) increased, creatinine increased, gamma glutamyl transferase(GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesmia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased and serum amylase increased. Laboratory abnormality graded as per NCI CTCAE v4.03; G0=non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported. Only non-zero categories for any reporting arm are reported.
Time frame: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)
Change From Baseline in Vital Signs - Blood Pressure at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.
Time frame: Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)
Change From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and EOT Visit
Pulse rate was measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.
Time frame: Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)
Number of Participants Who Discontinued Treatment Due to Toxicity
Number of participants who discontinued treatment due to toxicity are reported in this outcome measure.
Time frame: From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)
Time to Treatment Discontinuation/Failure Due to Toxicity
Time to treatment discontinuation/ failure due to toxicity was defined as the time from first dose of study treatment to discontinuation of study treatment due to an adverse event or death due to study treatment toxicity.
Time frame: From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)
Trough Plasma Concentration (Ctrough) of Avelumab
Predose concentration during multiple dosing.
Time frame: Pre dose (0 hour) on Day 1, 15 and 29 of Cycle 1, Day 1 and 29 of Cycles 2, 3, 4 and Day 1 of Cycle 6
Ctrough of Axitinib
Predose concentration during multiple dosing.
Time frame: Pre dose (0 hour) on day 15 and 29 of cycle 1 (each cycle= 6 weeks)
Maximum Plasma Concentration (Cmax) of Axitinib
Time frame: 2 hours post-dose on Day 1, pre-dose and 2 hours post dose on Days 15 and 29 of Cycle 1
Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue
Tumor biospecimens from pre-treatment tissue samples were analyzed by immunohistochemistry for PD-L1 biomarker expression. Number of participants with positive PD-L1 biomarker expression are reported in this outcome measure.
Time frame: At screening
PFS in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups
PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)
Percentage of Participants With OR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups
OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
Time frame: From date of randomization until PD (maximum up to approximately 26 months)
Percentage of Participants With DC in Biomarker-Positive Subgroup
DC was defined as a best overall response of CR, PR, or stable disease (SD) according to the RECIST v.1.1 recorded from randomization until disease progression or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. SD was defined as PR that the sum increases by less than 20% from the nadir, (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.
Time frame: From date of randomization until PD or death, whichever occurred first (maximum up to approximately 26 months)
TTR in Biomarker-Positive Subgroup
TTR was defined as the time from randomization to the first documentation of objective tumor response (CR or PR) according to RECIST v1.1 which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
Time frame: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)
DR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups
DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause, whichever occurred first. As per RECIST version 1.1, CR: disappearance of all target and non-target lesions, and sustained for at least 4 weeks. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 mm. PR: at least 30%\< in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD: defined as at least a 20% \> in sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm. Appearance of one or more new lesions was also considered progression.
Time frame: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)
Number of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) of Avelumab When Used in Combination With Axitinib
Time frame: From start of treatment until 30 days after the end of avelumab treatment (maximum up to approximately 89 months)
Time to Symptom Deterioration (TTD) for Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS)
TTD was defined as the time from date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS. FKSI was used to assess symptoms and quality of life (QoL) for those diagnosed with advanced kidney cancer and it consisted of 19 questions. A 9-item subscale of the FKSI known as FKSI-Disease Related Symptoms subscale (FKSI-DRS). This subscale included 9 items: lack of energy, pain, losing weight, bone pain, fatigue, shortness of breath, coughing, bothered by fevers, and hematuria. Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher score indicated greater presence of symptoms.
Time frame: Date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS (maximum up to approximately 26 months)
Change From Baseline in European Quality of Life (EuroQol) 5-Dimension 5 Levels (EQ-5D-5L) Utility Score
EQ-5D-5L is a 5-item participant-completed questionnaire designed to assess health status in terms of a single utility score. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Overall scores ranged from 0 to 1, with low scores representing a higher level of dysfunction. Published UK weights were used to create a single summary utility score. Utility scores range from -0.594 to 1, with higher scores representing better health status.
Time frame: Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Score
EQ-VAS records the participant's self-rated health status from 0 (worst imaginable health status) to 100 (best imaginable health status), where higher scores indicated better health status.
Time frame: Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)
| Milestone | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Started | 442 | 444 |
| Completed | 0 | 0 |
| Not completed | 442 | 444 |
| Withdrew: Other | 18 | 6 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 1 |
| Withdrew: No longer met eligibility criteria | 6 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 25 | 22 |
| Withdrew: Global deterioration of health status | 18 | 20 |
| Withdrew: Physician decision | 15 | 8 |
| Withdrew: Adverse event | 86 | 65 |
| Withdrew: Withdrawal by subject | 29 | 43 |
| Withdrew: Progressive disease | 236 | 266 |
| Withdrew: Participation terminated by sponsor | 6 | 9 |
PFS: time from the date of randomization to the date of the first documentation of progressive disease (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1) or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20 percent (%), increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute more than (\>) of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants | 13.8 (11.1 to NA) | 7.2 (5.7 to 9.7) |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Overall Survival (OS) in PD-L1 Positive Participants | 43.2 (36.5 to 51.7) | 36.2 (29.8 to 44.2) |
PFS: time from the date of randomization to the date of the first documentation of PD or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| PFS as Assessed by BICR in Participants Irrespective of PD-L1 Expression | 13.8 (11.1 to NA) | 8.4 (6.9 to 11.1) |
OS was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| OS in Participants Irrespective of PD-L1 Expression | 44.8 (39.7 to 51.1) | 38.9 (31.4 to 45.2) |
OR was defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Percentage of Participants With Objective Response (OR) as Assessed by BICR Irrespective of PD-L1 Expression | 51.4 (46.6 to 56.1) | 25.7 (21.7 to 30.0) |
OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by investigator recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Percentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression | 59.7 (55.0 to 64.3) | 32.0 (27.7 to 36.5) |
DC was defined as a best overall response of CR, PR, non-CR/non-PD or stable disease (SD) according to RECIST v1.1 as assessed by BICR. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.
| Percentage of participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Percentage of Participants With Disease Control (DC) as Assessed by BICR Irrespective of PD-L1 Expression | 82.8 (79.0 to 86.2) | 73.4 (69.1 to 77.5) |
DC was defined as a best overall response of CR, PR, non-CR/non-PD or SD according to RECIST v1.1 as assessed by investigator. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.
| Percentage of participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Percentage of Participants With DC as Assessed by Investigator Irrespective of PD-L1 Expression | 85.1 (81.4 to 88.3) | 76.4 (72.1 to 80.2) |
TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by BICR (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Time to Tumor Response (TTR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression | 2.6 (1.2 to 13.8) | 3.2 (1.2 to 11.6) |
TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by investigator (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| TTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression | 2.8 (1.1 to 34.5) | 2.8 (1.2 to 65.2) |
BICR assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression assessed by BICR or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Duration of Response (DR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression | NA (NA to NA) | NA (11.2 to NA) |
Investigator assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression (PD) assessed by investigator or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| DR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression | 19.4 (16.4 to 22.3) | 14.5 (8.7 to 16.6) |
Investigator assessed PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| PFS as Assessed by Investigator in Participants Irrespective of PD-L1 Expression | 13.9 (11.1 to 16.6) | 8.5 (8.2 to 9.7) |
PFS2 is defined as the time (in months) from randomization to discontinuation of next-line treatment after first objective disease progression by investigator assessment, second objective disease progression by investigator assessment after initiation of next-line treatment, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Progression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression | 30.4 (25.8 to 34.6) | 19.4 (17.0 to 22.4) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event was during the on-treatment period (time from the first dose of study treatment through 90 days after last dose of study treatment or start day of new anti-cancer drug therapy-1 day). As per NCI-CTCAE v4.03, grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death.
| Participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Grade 1 | 5 | 17 |
| Grade 2 | 64 | 73 |
| Grade 3 | 271 | 268 |
| Grade 4 | 64 | 54 |
| Grade 5 | 30 | 24 |
Following hematology parameters were assessed: hemoglobin decreased (anemia), hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell (WBC) decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 4.03 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Baseline was defined as last assessment prior to first dose of study treatment. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.
| Participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Anemia (Baseline G0 to post-baseline G3-4) | 3 | 9 |
| Anemia (Baseline G1 to post-baseline G3-4) | 6 | 21 |
| Anemia (Baseline G2 to post-baseline G3-4) | 4 | 14 |
| Anemia (Baseline G3 to post-baseline G3-4) | 0 | 2 |
| Lymphocytes count decreased (Baseline G0 to post-baseline G3-4) | 21 | 53 |
| Lymphocytes count decreased (Baseline G1 to post-baseline G3-4) | 11 | 18 |
| Lymphocytes count decreased (Baseline G2 to post-baseline G3-4) | 7 | 15 |
| Lymphocytes count decreased (Baseline G3 to post-baseline G3-4) | 2 | 6 |
| Neutrophils count decreased (Baseline G0 to post-baseline G3-4) | 7 | 108 |
| Neutrophils count decreased (Baseline G1 to post-baseline G3-4) | 0 | 2 |
| Neutrophils count decreased (Baseline G2 to post-baseline G3-4) | 0 | 1 |
| Platelets count decreased (Baseline G0 to post-baseline G3-4) | 3 | 61 |
| Platelets count decreased (Baseline G1 to post-baseline G3-4) | 1 | 6 |
| WBC decreased (Baseline G0 to post-baseline G3-4) | 1 | 35 |
| WBC decreased (Baseline G1 to post-baseline G3-4) | 0 | 7 |
| WBC decreased (Baseline G2 to post-baseline G3-4) | 0 | 2 |
Following chemistry parameters were assessed: alanine aminotransferase(ALT) increased, alkaline phosphatase(ALP) increased, aspartate aminotransferase(AST) increased, blood bilirubin increased, cholesterol high, creatinine phosphokinase(CPK) increased, creatinine increased, gamma glutamyl transferase(GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesmia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased and serum amylase increased. Laboratory abnormality graded as per NCI CTCAE v4.03; G0=non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported. Only non-zero categories for any reporting arm are reported.
| Participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| ALT increased (Baseline G0 to post-baseline G3-4) | 42 | 19 |
| ALT increased (Baseline G1 to post-baseline G3-4) | 3 | 0 |
| ALP increased (Baseline G0 to post-baseline G3-4) | 9 | 0 |
| ALP increased (Baseline G1 to post-baseline G3-4) | 5 | 6 |
| ALP increased (Baseline G2 to post-baseline G3-4) | 1 | 3 |
| ALP increased (Baseline G3 to post-baseline G3-4) | 4 | 1 |
| AST increased (Baseline G0 to post-baseline G3-4) | 26 | 16 |
| AST increased (Baseline G1 to post-baseline G3-4) | 6 | 4 |
| AST increased (Baseline G3 to post-baseline G3-4) | 1 | 0 |
| Blood bilirubin increased (Baseline G0 to post-baseline G3-4) | 3 | 6 |
| Blood bilirubin increased (Baseline G1 to post-baseline G3-4) | 2 | 0 |
| Cholesterol high (Baseline G0 to post-baseline G3-4) | 8 | 3 |
| Cholesterol high (Baseline G1 to post-baseline G3-4) | 4 | 3 |
| Cholesterol high (Baseline G2 to post-baseline G3-4) | 0 | 1 |
| CPK increased (Baseline G0 to post-baseline G3-4) | 7 | 7 |
| CPK increased (Baseline G2 to post-baseline G3-4) | 0 | 1 |
| CPK increased (Baseline G1 to post-baseline G3-4) | 0 | 2 |
| CPK increased (Baseline G3 to post-baseline G3-4) | 1 | 0 |
| Creatinine increased (Baseline G0 to post-baseline G3-4) | 7 | 2 |
| Creatinine increased (Baseline G1 to post-baseline G3-4) | 4 | 5 |
| Creatinine increased (Baseline G2 to post-baseline G3-4) | 0 | 1 |
| Creatinine increased (Baseline G3 to post-baseline G3-4) | 0 | 1 |
| GGT increased (Baseline G0 to post-baseline G3-4) | 15 | 16 |
| GGT increased (Baseline G1 to post-baseline G3-4) | 20 | 7 |
| GGT increased (Baseline G2 to post-baseline G3-4) | 12 | 4 |
| GGT increased (Baseline G3 to post-baseline G3-4) | 7 | 2 |
| GGT increased (Baseline G4 to post-baseline G3-4) | 0 | 1 |
| Hypercalcemia (Baseline G0 to post-baseline G3-4) | 4 | 4 |
| Hypercalcemia (Baseline G1 to post-baseline G3-4) | 1 | 2 |
| Hypercalcemia (Baseline G2 to post-baseline G3-4) | 1 | 1 |
| Hypercalcemia (Baseline G3 to post-baseline G3-4) | 0 | 2 |
| Hypercalcemia (Baseline G4 to post-baseline G3-4) | 0 | 1 |
| Hyperglycemia (Baseline G0 to post-baseline G3-4) | 37 | 20 |
| Hyperglycemia (Baseline G1 to post-baseline G3-4) | 4 | 3 |
| Hyperglycemia (Baseline G2 to post-baseline G3-4) | 5 | 3 |
| Hyperglycemia (Baseline G3 to post-baseline G3-4) | 6 | 4 |
| Hyperkalemia (Baseline G0 to post-baseline G3-4) | 19 | 16 |
| Hyperkalemia (Baseline G1 to post-baseline G3-4) | 1 | 5 |
| Hyperkalemia (Baseline G2 to post-baseline G3-4) | 3 | 3 |
| Hyperkalemia (Baseline G3 to post-baseline G3-4) | 1 | 0 |
| Hyperkalemia (Baseline G4 to post-baseline G3-4) | 0 | 1 |
| Hypermagnesemia (Baseline G0 to post-baseline G3-4) | 13 | 20 |
| Hypermagnesemia (Baseline G1 to post-baseline G3-4) | 1 | 2 |
| Hypernatremia (Baseline G0 to post-baseline G3-4) | 7 | 2 |
| Hypertriglyceridemia (Baseline G0 to post-baseline G3-4) | 18 | 3 |
| Hypertriglyceridemia (Baseline G1 to post-baseline G3-4) | 31 | 23 |
| Hypertriglyceridemia (Baseline G2 to post-baseline G3-4) | 15 | 6 |
| Hypertriglyceridemia (Baseline G3 to post-baseline G3-4) | 4 | 5 |
| Hypertriglyceridemia (Baseline G4 to post-baseline G3-4) | 0 | 1 |
| Hypoalbunemia (Baseline G0 to post-baseline G3-4) | 3 | 6 |
| Hypoalbunemia (Baseline G1 to post-baseline G3-4) | 1 | 1 |
| Hypoalbunemia (Baseline G2 to post-baseline G3-4) | 2 | 2 |
| Hypoalbunemia (Baseline G3 to post-baseline G3-4) | 1 | 2 |
| Hypocalcemia (Baseline G0 to post-baseline G3-4) | 4 | 4 |
| Hypocalcemia (Baseline G1 to post-baseline G3-4) | 0 | 1 |
| Hypocalcemia (Baseline G2 to post-baseline G3-4) | 1 | 0 |
| Hypoglycemia (Baseline G0 to post-baseline G3-4) | 2 | 1 |
| Hypokalemia (Baseline G0 to post-baseline G3-4) | 17 | 15 |
| Hypokalemia (Baseline G2 to post-baseline G3-4) | 2 | 1 |
| Hypomagnesemia (Baseline G0 to post-baseline G3-4) | 3 | 1 |
| Hypomagnesemia (Baseline G1 to post-baseline G3-4) | 2 | 1 |
| Hypomagnesemia (Baseline G2 to post-baseline G3-4) | 1 | 0 |
| Hyponatremia (Baseline G0 to post-baseline G3-4) | 42 | 35 |
| Hyponatremia (Baseline G1 to post-baseline G3-4) | 19 | 14 |
| Hyponatremia (Baseline G3 to post-baseline G3-4) | 1 | 2 |
| Lipase increased (Baseline G0 to post-baseline G3-4) | 63 | 27 |
| Lipase increased (Baseline G1 to post-baseline G3-4) | 19 | 8 |
| Lipase increased (Baseline G2 to post-baseline G3-4) | 7 | 3 |
| Lipase increased (Baseline G3 to post-baseline G3-4) | 2 | 7 |
| Lipase increased (Baseline G4 to post-baseline G3-4) | 1 | 0 |
| Serum amylase increased (Baseline G0 to post-baseline G3-4) | 21 | 4 |
| Serum amylase increased (Baseline G1 to post-baseline G3-4) | 12 | 4 |
| Serum amylase increased (Baseline G2 to post-baseline G3-4) | 4 | 4 |
| Serum amylase increased (Baseline G3 to post-baseline G3-4) | 1 | 3 |
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.
| Millimeters of mercury | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Baseline: Sitting SBP | 126.5 ± 13.52 | 126.3 ± 12.00 |
| Change at Cycle 2, Day 1: Sitting SBP | 4.7 ± 16.08 | 0.8 ± 12.49 |
| Change at Cycle 3, Day 1: Sitting SBP | 3.8 ± 16.43 | 1.2 ± 12.81 |
| Change at Cycle 4, Day 1: Sitting SBP | 3.0 ± 15.95 | 0.1 ± 13.01 |
| Change at Cycle 5, Day 1: Sitting SBP | 2.5 ± 15.42 | -0.1 ± 12.26 |
| Change at Cycle 6, Day 1: Sitting SBP | 1.6 ± 15.39 | -0.1 ± 12.97 |
| Change at Cycle 7, Day 1: Sitting SBP | 1.9 ± 15.39 | 0.4 ± 13.56 |
| Change at End of Treatment: Sitting SBP | 0.9 ± 17.40 | 1.7 ± 15.67 |
| Baseline: Sitting DBP | 75.7 ± 9.32 | 75.9 ± 9.41 |
| Change at Cycle 2, Day 1: Sitting DBP | 5.8 ± 10.92 | -0.1 ± 8.60 |
| Change at Cycle 3, Day 1: Sitting DBP | 4.9 ± 10.98 | 0.0 ± 9.64 |
| Change at Cycle 4, Day 1: Sitting DBP | 4.8 ± 11.61 | -1.9 ± 9.30 |
| Change at Cycle 5, Day 1: Sitting DBP | 4.5 ± 11.17 | -1.9 ± 9.71 |
| Change at Cycle 6, Day 1: Sitting DBP | 3.8 ± 10.18 | -1.3 ± 9.89 |
| Change at Cycle 7, Day 1: Sitting DBP | 3.8 ± 11.04 | -1.1 ± 9.90 |
| Change at End of Treatment: Sitting DBP | 1.5 ± 12.70 | -0.9 ± 10.92 |
Pulse rate was measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.
| beats per minute | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Baseline | 75.4 ± 12.49 | 75.6 ± 12.63 |
| Change at Cycle 2, Day 1 | 0.4 ± 12.77 | 3.1 ± 10.69 |
| Change at Cycle 3, Day 1 | 0.8 ± 12.58 | 3.1 ± 11.34 |
| Change at Cycle 4, Day 1 | -0.6 ± 12.79 | 2.8 ± 10.34 |
| Change at Cycle 5, Day 1 | -0.5 ± 12.00 | 2.5 ± 10.82 |
| Change at Cycle 6, Day 1 | -1.9 ± 12.37 | 1.6 ± 10.75 |
| Change at Cycle 7, Day 1 | -1.9 ± 11.69 | 2.1 ± 10.13 |
| Change at End of Treatment | 2.9 ± 15.29 | 3.5 ± 12.27 |
Number of participants who discontinued treatment due to toxicity are reported in this outcome measure.
| Participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Number of Participants Who Discontinued Treatment Due to Toxicity | 136 (17.41 to —) | 65 (12.82 to —) |
Time to treatment discontinuation/ failure due to toxicity was defined as the time from first dose of study treatment to discontinuation of study treatment due to an adverse event or death due to study treatment toxicity.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Time to Treatment Discontinuation/Failure Due to Toxicity | 13.5 ± 17.41 | 10.5 ± 12.82 |
Predose concentration during multiple dosing.
| Micrograms per milliliter | Avelumab + Axitinib |
|---|---|
| Cycle 1 (day 1) | 4.218 ± 1232 |
| Cycle 1 (day 15) | 18.69 ± 102 |
| Cycle 1 (day 29) | 21.99 ± 96 |
| Cycle 2 (day 1) | 24.87 ± 92 |
| Cycle 2 (day 29) | 22.62 ± 113 |
| Cycle 3 (day 1) | 26.04 ± 98 |
| Cycle 3 (day 29) | 30.13 ± 82 |
| Cycle 4 (day 1) | 29.15 ± 98 |
| Cycle 4 (day 29) | 31.38 ± 86 |
| Cycle 6 (day 1) | 39.11 ± 58 |
Predose concentration during multiple dosing.
| Nanograms per milliliter | Avelumab + Axitinib |
|---|---|
| Cycle1 (day 15) | 4.904 ± 172 |
| Cycle1 (day 29) | 6.272 ± 174 |
| Nanogram per milliliter | Avelumab + Axitinib |
|---|---|
| Cycle1 (day 1); Post Dose | 17.93 ± 182 |
| Cycle1 (day 15); Pre-Dose | 4.904 ± 172 |
| Cycle1 (day 15); Post Dose | 18.45 ± 157 |
| Cycle1 (day 29); Pre-Dose | 6.272 ± 174 |
| Cycle1 (day 29); Post Dose | 17.19 ± 174 |
Tumor biospecimens from pre-treatment tissue samples were analyzed by immunohistochemistry for PD-L1 biomarker expression. Number of participants with positive PD-L1 biomarker expression are reported in this outcome measure.
| Participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue | 266 | 288 |
PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| PD-L1 Positive Tumors | 13.8 (11.1 to NA) | 7.2 (5.7 to 9.7) |
| PD-L1 Negative Tumors | 16.1 (9.7 to NA) | 11.1 (6.9 to 17.3) |
OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
| Percentage of participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| PD-L1 Positive Tumors | 55.2 (49.0 to 61.2) | 25.5 (20.6 to 30.9) |
| PD-L1 Negative Tumors | 47.0 (38.2 to 55.8) | 28.3 (20.5 to 37.3) |
DC was defined as a best overall response of CR, PR, or stable disease (SD) according to the RECIST v.1.1 recorded from randomization until disease progression or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. SD was defined as PR that the sum increases by less than 20% from the nadir, (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.
| Percentage of participants | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Percentage of Participants With DC in Biomarker-Positive Subgroup | 84.4 (79.6 to 88.6) | 71.0 (65.4 to 76.2) |
TTR was defined as the time from randomization to the first documentation of objective tumor response (CR or PR) according to RECIST v1.1 which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| TTR in Biomarker-Positive Subgroup | 1.6 (1.2 to 10.1) | 3.0 (1.2 to 11.6) |
DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause, whichever occurred first. As per RECIST version 1.1, CR: disappearance of all target and non-target lesions, and sustained for at least 4 weeks. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 mm. PR: at least 30%\< in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD: defined as at least a 20% \> in sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm. Appearance of one or more new lesions was also considered progression.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| PD-L1 Positive Tumors | NA (NA to NA) | NA (10.9 to NA) |
| PD-L1 Negative Tumors | NA (11.1 to NA) | NA (9.0 to NA) |
| Participants | Avelumab + Axitinib |
|---|---|
| ADA Positive | 77 |
| nAb Positive | 51 |
TTD was defined as the time from date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS. FKSI was used to assess symptoms and quality of life (QoL) for those diagnosed with advanced kidney cancer and it consisted of 19 questions. A 9-item subscale of the FKSI known as FKSI-Disease Related Symptoms subscale (FKSI-DRS). This subscale included 9 items: lack of energy, pain, losing weight, bone pain, fatigue, shortness of breath, coughing, bothered by fevers, and hematuria. Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher score indicated greater presence of symptoms.
| Months | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Time to Symptom Deterioration (TTD) for Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS) | 4.2 (4.2 to 5.7) | 6.3 (5.5 to 8.3) |
EQ-5D-5L is a 5-item participant-completed questionnaire designed to assess health status in terms of a single utility score. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Overall scores ranged from 0 to 1, with low scores representing a higher level of dysfunction. Published UK weights were used to create a single summary utility score. Utility scores range from -0.594 to 1, with higher scores representing better health status.
| Units on a scale | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Cycle 2 (Day 1) | -0.034 ± 0.1743 | 0.001 ± 0.1632 |
| Cycle 3 (Day 1) | -0.023 ± 0.1826 | -0.017 ± 0.1804 |
| Cycle 4 (Day 1) | -0.029 ± 0.1829 | -0.022 ± 0.1667 |
| Cycle 5 (Day 1) | -0.019 ± 0.1622 | -0.016 ± 0.1826 |
| Cycle 6 (Day 1) | -0.025 ± 0.1787 | -0.003 ± 0.1967 |
| Cycle 7 (Day 1) | -0.018 ± 0.1651 | 0.008 ± 0.1618 |
| Cycle 8 (Day 1) | -0.029 ± 0.1848 | 0.002 ± 0.1731 |
| Cycle 9 (Day 1) | -0.029 ± 0.2021 | -0.011 ± 0.1662 |
| Cycle 10 (Day 1) | -0.025 ± 0.1935 | -0.018 ± 0.1617 |
| Cycle 11 (Day 1) | -0.020 ± 0.1854 | 0.004 ± 0.1642 |
| Cycle 12 (Day 1) | -0.026 ± 0.1875 | -0.016 ± 0.1712 |
| Cycle 13 (Day 1) | -0.026 ± 0.1777 | -0.017 ± 0.1549 |
| Cycle 14 (Day 1) | -0.036 ± 0.1938 | -0.006 ± 0.1600 |
| Cycle 15 (Day 1) | -0.036 ± 0.1892 | 0.018 ± 0.1487 |
| Cycle 16 (Day 1) | -0.044 ± 0.1757 | 0.020 ± 0.1663 |
| Cycle 17 (Day 1) | -0.050 ± 0.1950 | -0.000 ± 0.1675 |
| Cycle 18 (Day 1) | -0.040 ± 0.1667 | -0.027 ± 0.1765 |
| Cycle 19 (Day 1) | -0.059 ± 0.1959 | 0.003 ± 0.1665 |
| Cycle 20 (Day 1) | -0.050 ± 0.1942 | 0.001 ± 0.1538 |
| Cycle 21 (Day 1) | -0.048 ± 0.1902 | -0.004 ± 0.1904 |
| Cycle 22 (Day 1) | 0.037 ± 0.1919 | 0.002 ± 0.1561 |
| Cycle 23 (Day 1) | -0.033 ± 0.2021 | -0.028 ± 0.1729 |
| Cycle 24 (Day 1) | -0.036 ± 0.1982 | 0.004 ± 0.1618 |
| Cycle 25 (Day 1) | -0.019 ± 0.1825 | -0.007 ± 0.1678 |
| Cycle 26 (Day 1) | -0.039 ± 0.1927 | -0.009 ± 0.1471 |
| Cycle 27 (Day 1) | -0.046 ± 0.2233 | 0.014 ± 0.1492 |
| Cycle 28 (Day 1) | -0.039 ± 0.2060 | -0.007 ± 0.1639 |
| Cycle 29 (Day 1) | -0.019 ± 0.2095 | 0.017 ± 0.1601 |
| Cycle 30 (Day 1) | -0.032 ± 0.2244 | -0.003 ± 0.1557 |
| Cycle 31 (Day 1) | -0.042 ± 0.2246 | -0.009 ± 0.1508 |
| Cycle 32 (Day 1) | -0.044 ± 0.2095 | 0.032 ± 0.1255 |
| Cycle 33 (Day 1) | -0.051 ± 0.2294 | -0.060 ± 0.3550 |
| Cycle 34 (Day 1) | -0.029 ± 0.1776 | 0.038 ± 0.1558 |
| Cycle 35 (Day 1) | -0.010 ± 0.1442 | -0.002 ± 0.1610 |
| Cycle 36 (Day 1) | -0.016 ± 0.1599 | 0.030 ± 0.1551 |
| Cycle 37 (Day 1) | -0.027 ± 0.1507 | 0.052 ± 0.1601 |
| Cycle 38 (Day 1) | -0.016 ± 0.1459 | 0.057 ± 0.1666 |
| Cycle 39 (Day 1) | -0.042 ± 0.1569 | 0.052 ± 0.1386 |
| Cycle 40 (Day 1) | -0.021 ± 0.1484 | 0.060 ± 0.1232 |
| Cycle 41 (Day 1) | -0.030 ± 0.1492 | 0.056 ± 0.1853 |
| Cycle 42 (Day 1) | -0.021 ± 0.1634 | 0.034 ± 0.1585 |
| Cycle 43 (Day 1) | -0.031 ± 0.1334 | 0.011 ± 0.2062 |
| Cycle 44 (Day 1) | -0.028 ± 0.1300 | 0.016 ± 0.2114 |
| Cycle 45 (Day 1) | -0.050 ± 0.1442 | 0.007 ± 0.2191 |
| Cycle 46 (Day 1) | -0.042 ± 0.1380 | -0.007 ± 0.2495 |
| Cycle 47 (Day 1) | -0.019 ± 0.1240 | -0.015 ± 0.2335 |
| Cycle 48 (Day 1) | -0.025 ± 0.1566 | 0.009 ± 0.2833 |
| Cycle 49 (Day 1) | -0.028 ± 0.1356 | 0.010 ± 0.1873 |
| Cycle 50 (Day 1) | -0.028 ± 0.1359 | 0.028 ± 0.2507 |
| Cycle 51 (Day 1) | -0.011 ± 0.1304 | -0.010 ± 0.2594 |
| Cycle 52 (Day 1) | -0.036 ± 0.1265 | -0.035 ± 0.2524 |
| Cycle 53 (Day 1) | -0.084 ± 0.1437 | 0.048 ± 0.1308 |
| Cycle 54 (Day 1) | -0.040 ± 0.1425 | 0.078 ± 0.1157 |
| Cycle 55 (Day 1) | -0.046 ± 0.1121 | 0.051 ± 0.1060 |
| Cycle 56 (Day 1) | -0.083 ± 0.1081 | 0.025 ± 0.1796 |
| Cycle 57 (Day 1) | -0.104 ± 0.1347 | 0.031 ± NA |
| Cycle 58 (Day 1) | -0.078 ± 0.1408 | 0.031 ± NA |
| Cycle 59 (Day 1) | -0.106 ± 0.1053 | — |
| Cycle 60 (Day 1) | -0.040 ± 0.1167 | — |
| End of Treatment | -0.111 ± 0.2464 | -0.069 ± 0.2375 |
EQ-VAS records the participant's self-rated health status from 0 (worst imaginable health status) to 100 (best imaginable health status), where higher scores indicated better health status.
| Units on a scale | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| Cycle 2 (Day 1) | -0.9 ± 16.12 | -0.2 ± 15.85 |
| Cycle 3 (Day 1) | -0.4 ± 16.39 | 0.4 ± 16.44 |
| Cycle 4 (Day 1) | -0.1 ± 17.23 | 0.7 ± 17.26 |
| Cycle 5 (Day 1) | 0.4 ± 16.66 | 1.8 ± 16.16 |
| Cycle 6 (Day 1) | 1.3 ± 16.05 | 2.6 ± 15.35 |
| Cycle 7 (Day 1) | 1.2 ± 16.34 | 3.3 ± 14.91 |
| Cycle 8 (Day 1) | 1.4 ± 16.54 | 2.9 ± 13.84 |
| Cycle 9 (Day 1) | 2.0 ± 16.06 | 3.3 ± 13.77 |
| Cycle 10 (Day 1) | 1.6 ± 15.12 | 2.4 ± 14.46 |
| Cycle 11 (Day 1) | 2.5 ± 15.70 | 4.1 ± 12.91 |
| Cycle 12 (Day 1) | 2.1 ± 14.72 | 2.6 ± 14.59 |
| Cycle 13 (Day 1) | 3.0 ± 14.39 | 2.7 ± 14.29 |
| Cycle 14 (Day 1) | 2.7 ± 15.07 | 3.0 ± 13.98 |
| Cycle 15 (Day 1) | 3.1 ± 14.97 | 4.7 ± 13.63 |
| Cycle 16 (Day 1) | 2.9 ± 15.08 | 3.6 ± 14.02 |
| Cycle 17 (Day 1) | 3.0 ± 15.44 | 3.2 ± 12.88 |
| Cycle 18 (Day 1) | 3.2 ± 15.31 | 2.0 ± 13.69 |
| Cycle 19 (Day 1) | 4.5 ± 15.61 | 3.0 ± 13.10 |
| Cycle 20 (Day 1) | 3.9 ± 15.15 | 3.1 ± 12.58 |
| Cycle 21 (Day 1) | 3.7 ± 16.30 | 2.1 ± 13.00 |
| Cycle 22 (Day 1) | 4.3 ± 16.43 | 2.6 ± 12.82 |
| Cycle 23 (Day 1) | 3.7 ± 16.90 | 1.3 ± 15.16 |
| Cycle 24 (Day 1) | 3.3 ± 18.70 | 4.5 ± 13.45 |
| Cycle 25 (Day 1) | 4.6 ± 15.28 | 4.2 ± 14.42 |
| Cycle 26 (Day 1) | 4.4 ± 17.10 | 3.4 ± 13.00 |
| Cycle 27 (Day 1) | 4.7 ± 16.59 | 5.4 ± 13.43 |
| Cycle 28 (Day 1) | 6.3 ± 16.08 | 5.0 ± 13.84 |
| Cycle 29 (Day 1) | 4.8 ± 15.44 | 5.4 ± 14.24 |
| Cycle 30 (Day 1) | 6.0 ± 15.78 | 5.3 ± 14.61 |
| Cycle 31 (Day 1) | 5.7 ± 15.42 | 5.2 ± 14.88 |
| Cycle 32 (Day 1) | 5.4 ± 16.35 | 6.0 ± 13.57 |
| Cycle 33 (Day 1) | 5.5 ± 16.07 | 3.6 ± 20.61 |
| Cycle 34 (Day 1) | 4.8 ± 15.25 | 6.1 ± 15.91 |
| Cycle 35 (Day 1) | 6.0 ± 14.53 | 6.4 ± 15.61 |
| Cycle 36 (Day 1) | 6.0 ± 15.63 | 5.2 ± 17.11 |
| Cycle 37 (Day 1) | 5.8 ± 14.63 | 4.5 ± 15.86 |
| Cycle 38 (Day 1) | 5.3 ± 14.58 | 4.3 ± 17.58 |
| Cycle 39 (Day 1) | 5.3 ± 14.04 | 5.9 ± 15.75 |
| Cycle 40 (Day 1) | 6.0 ± 15.00 | 4.7 ± 18.17 |
| Cycle 41 (Day 1) | 5.6 ± 13.69 | 6.2 ± 18.37 |
| Cycle 42 (Day 1) | 5.3 ± 13.68 | 5.4 ± 18.19 |
| Cycle 43 (Day 1) | 6.6 ± 11.64 | 5.4 ± 20.14 |
| Cycle 44 (Day 1) | 4.9 ± 13.38 | 5.1 ± 19.77 |
| Cycle 45 (Day 1) | 6.3 ± 12.55 | 1.5 ± 17.97 |
| Cycle 46 (Day 1) | 6.7 ± 13.25 | 0.3 ± 19.31 |
| Cycle 47 (Day 1) | 5.4 ± 11.10 | 2.5 ± 18.07 |
| Cycle 48 (Day 1) | 4.4 ± 11.73 | 3.5 ± 21.77 |
| Cycle 49 (Day 1) | 4.2 ± 12.21 | 1.9 ± 21.42 |
| Cycle 50 (Day 1) | 4.8 ± 13.07 | 2.9 ± 20.53 |
| Cycle 51 (Day 1) | 5.8 ± 12.36 | 2.1 ± 22.93 |
| Cycle 52 (Day 1) | 4.2 ± 11.37 | 1.5 ± 19.94 |
| Cycle 53 (Day 1) | 3.2 ± 11.43 | 7.7 ± 16.22 |
| Cycle 54 (Day 1) | 4.6 ± 11.54 | 7.5 ± 13.34 |
| Cycle 55 (Day 1) | 4.6 ± 11.65 | 7.8 ± 17.89 |
| Cycle 56 (Day 1) | -0.6 ± 8.08 | -6.0 ± 5.66 |
| Cycle 57 (Day 1) | -1.9 ± 10.67 | -2.0 ± NA |
| Cycle 58 (Day 1) | -2.1 ± 8.59 | -2.0 ± NA |
| Cycle 59 (Day 1) | 0.0 ± 9.35 | — |
| Cycle 60 (Day 1) | -1.7 ± 16.07 | — |
| End of treatment | -5.0 ± 19.92 | -4.3 ± 19.63 |
Collected over From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Avelumab + Axitinib | 284/442 (64.3%) | 231/434 (53.2%) | 429/434 (98.8%) |
| Sunitinib | 296/444 (66.7%) | 166/439 (37.8%) | 433/439 (98.6%) |
| Event | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 12/434 | 3/439 |
| Abdominal painGastrointestinal disorders | 2/434 | 12/439 |
| Acute myocardial infarctionCardiac disorders | 11/434 | 0/439 |
| Disease progressionGeneral disorders | 10/434 | 7/439 |
| AnaemiaBlood and lymphatic system disorders | 1/434 | 10/439 |
| Acute kidney injuryRenal and urinary disorders | 9/434 | 9/439 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/434 | 6/439 |
| Acute coronary syndromeCardiac disorders | 6/434 | 0/439 |
| Atrial fibrillationCardiac disorders | 6/434 | 0/439 |
| Adrenal insufficiencyEndocrine disorders | 6/434 | 0/439 |
| Event | Avelumab + Axitinib | Sunitinib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 303/434 | 228/439 |
| HypertensionVascular disorders | 236/434 | 168/439 |
| FatigueGeneral disorders | 205/434 | 194/439 |
| NauseaGastrointestinal disorders | 186/434 | 185/439 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 160/434 | 162/439 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 157/434 | 83/439 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 148/434 | 20/439 |
| CoughRespiratory, thoracic and mediastinal disorders | 147/434 | 103/439 |
| Decreased appetiteMetabolism and nutrition disorders | 141/434 | 144/439 |
| HypothyroidismEndocrine disorders | 135/434 | 89/439 |
Full analysis set (FAS) included all randomized participants.
| Age, Continuous(Years) | Avelumab + Axitinib | Sunitinib | Total |
|---|---|---|---|
| Mean | 60.86 ± 9.95 | 60.66 ± 10.28 | 60.76 ± 10.11 |
| Sex: Female, Male(Participants) | Avelumab + Axitinib | Sunitinib | Total |
|---|---|---|---|
| Female | 126 | 100 | 226 |
| Male | 316 | 344 | 660 |
| Ethnicity (NIH/OMB)(Participants) | Avelumab + Axitinib | Sunitinib | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 18 | 37 |
| Not Hispanic or Latino | 388 | 377 | 765 |
| Unknown or Not Reported | 35 | 49 | 84 |
| Race (NIH/OMB)(Participants) | Avelumab + Axitinib | Sunitinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 4 | 8 |
| Asian | 70 | 63 | 133 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 10 | 10 | 20 |
| White | 332 | 334 | 666 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 26 | 32 | 58 |
Showing the first 100 of 270 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2016 to primary completion in Aug 2023, 89 months.
Results were first posted in Oct 2024, 1 year 1 month after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 89 months is above that.
Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Avelumab · Axitinib